GCGuillemette Clément

Guillemette Clément

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guillemette Clément has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Mathilde Renaud

    Service de Neurologie, Centre Hospitalier Universitaire Régional de Nancy, Nancy, France

    3 shared publications
  • Armand Hocquel

    Service de neurologie, centre hospitalier régional universitaire de Nancy, hôpital Central, Nancy, France

    2 shared publications
  • Bernard Brais

    Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada

    2 shared publications
  • Bernard Brais

    Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, Canada

    2 shared publications
  • Carine Pourié

    INSERM-U1256 NGERE, Université de Lorraine, Nancy, France

    2 shared publications
  • Céline Bonnet

    INSERM-U1256 NGERE, Université de Lorraine, Nancy, France

    2 shared publications

Latest Publications

  • Alzheimer's disease and nutrition: Focus on the impact of hyperhomocysteinemia

    by Guillemette Clément, Franck Hansmannel, Lucie Hopes, Carine Bossenmeyer-Pourié, Mathilde Renaud

    Alzheimer's disease (AD) is a multifactorial neurodegenerative disease. Despite advances in the understanding of the genetics of AD, environmental risk factors are still under investigation, and the etiology is still not completely understood. The environmental component of AD, which we explore in the first part of this review, takes on greater importance with more advanced disease onset. Moreover, genetics does not explain all of AD. Environmental risk factors are divided into modifiable and nonmodifiable risk factors. Among the modifiable risk factors, nutrition seems to play a predominant role. One-carbon metabolism (OCM) is involved in this food-related component, notably through B vitamins. Homocysteine, a sulfur-containing amino acid, is at the crossroads of OCM. Abnormal increases in homocysteine levels (hyperhomocysteinemia) are associated with deleterious effects on cognition. Various mechanisms can lead to hyperhomocysteinemia, including genetic factors associated with different polymorphisms, dietary deficiencies targeting vitamins B9 and B12, and renal insufficiency. The second part of the review details OCM and the role of homocysteine. Finally, part 3 highlights the numerous studies in the literature describing the association between hyperhomocysteinemia and cognitive decline. However, the mechanistic links between hyperhomocysteinemia and cognitive decline in AD are poorly understood. Several hypotheses have been proposed in the literature. The toxic effects of homocysteine could be mediated by N-homocysteinylation, a nonenzymatic reaction leading to the irreversible accumulation of N-homocysteinylated proteins. Finally, we detail some therapeutic trials targeting one-carbon metabolism in AD, notably vitamin B9 and B12 supplementation.

  • Cerebellar cognitive affective syndrome (CCAS) and [18F]-FDG PET findings in spinocerebellar ataxia type SCA27B

    by Laurine Cros, David Pellerin, Thomas Palpacuer, Salomé Puisieux, Solène Frismand, Armand Hocquel, Marion Wandzel, Virginie Roth, Carine Pourié, Bernard Brais, et al.

    Background Spinocerebellar ataxia type 27B (SCA27B) is caused by ≥ 250 GAA repeat expansions in intron 1 of the FGF14 gene. While motor symptoms are well documented, cognitive manifestations remain insufficiently explored. The cerebellar cognitive affective syndrome scale (CCAS scale) provides a framework for assessing cognition. Methods We conducted a prospective study at Nancy University Hospital. The primary objective was to determine the prevalence of cerebellar cognitive affective syndrome. We subsequently characterized the cognitive profile using a standardized neuropsychological battery, evaluated quality of life, and examined the associations between CCAS score, GAA repeat length, motor severity, and age at onset. A [18F]-FDG PET metabolic analysis was performed, including individual visual analysis, followed by a whole-brain voxel-by-voxel comparison between SCA27B patients, healthy controls, and MSA patients. Results Seventeen patients with genetically confirmed SCA27B were included. Motor symptoms were moderate (mean SARA score: 7 ± 6.2/40). Definite cerebellar cognitive affective syndrome (≥ 3 failed subtests) was identified in 41% (7/17) of the patients. The comprehensive neuropsychological evaluation revealed mild-to-moderate cognitive impairment; across all cognitive functions tested, fewer than 12% of patients showed cognitive impairment, except for social cognition (23.6%). The PET scan showed preserved cerebellar metabolism in individual analyses (2 patients with hypometabolism). Whole-brain voxel-based analysis, when compared to healthy controls, identified 5 clusters of hypometabolism, with no hypermetabolism. Conclusion This study is among the first to investigate cognitive impairment in patients with SCA27B using the CCAS scale and comprehensive neuropsychological testing. A substantial prevalence of cerebellar cognitive affective syndrome was observed, even if the decrease of cerebellar metabolic was modest. These findings highlight the need for systematic screening of cognitive and nonmotor symptoms to improve multidisciplinary management.


  • Open Access

    Involvement of the Superior Cerebellar Peduncles in GAA- FGF14 Ataxia

    by Shihan Chen, Catherine Ashton, Rawan Sakalla, Guillemette Clement, Sophie Planel, Céline Bonnet, Phillipa J. Lamont, Karthik Kulanthaivelu, Atchayaram Nalini, Henry Houlden, et al.

    GAA-FGF14 ataxia (SCA27B) is a recently reported late-onset ataxia caused by a GAA repeat expansion in intron 1 of the FGF14 gene. After the clinical observation of superior cerebellar peduncle (SCP) involvement in some affected patients, we sought to verify the prevalence of this finding in our cohort and 4 additional independent cohorts of patients with SCA27B. We performed a retrospective review of the brain MRI scans of a total of 87 patients (median age at MRI 69 years; range 28-88 years) from different independent cohorts to assess the presence of SCP involvement, defined as abnormally high T2 signal along the SCP tract. We observed SCP involvement in 52 patients (52/87; 59.8%) from all the cohorts combined. The finding was replicated at rates ranging from 50% to 62.8% in the cohorts taken separately. SCP involvement in SCA27B is frequent. Its detection may facilitate the diagnostic process of patients with SCA27B.


  • Open Access

    Oculomotor Findings in Spinocerebellar Ataxia 27B: A Case Series

    by Guillemette Clément, Salomé Puisieux, Catherine Ashton, David Pellerin, Matt C. Danzi, Céline Bonnet, Virginie Roth, Marion Wandzel, Armand Hocquel, Carine Pourié, et al.


  • Open Access

    Spinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia

    by G. Clément, S. Puisieux, D. Pellerin, B. Brais, C. Bonnet, M. Renaud


  • Le langage et les fluences verbales après stimulation cérébrale profonde des noyaux sous-thalamiques dans la maladie de Parkinson

    by Guillemette Clément, Thomas Wirth, Ouhaid Lagha-Boukbiza, Jimmy Voirin, Clélie Philipps, Nadine Longato, Mathieu Anheim

  • Language and verbal fluency outcome after bilateral subthalamic Nucleus Deep Brain Stimulation in Parkinson's disease

    by Guillemette Clément, Thomas Wirth, Lucile Haumesser, Marie Des Neiges Santin, Jimmy Voirin, Ouhaid Lagha-Boukbiza, Céline Labonne, Christine Tranchant, Nadine Longato, Clélie Phillipps, et al.